4.7 Article

Epidemiology of major depressive episode in a southern European country: Results from the ESEMeD-Spain project

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 120, 期 1-3, 页码 76-85

出版社

ELSEVIER
DOI: 10.1016/j.jad.2009.04.016

关键词

Depression; Spain; Epidemiology; Health surveys; Disability

资金

  1. European Commission [QLG5-1999-01042, SANCO 2004123]
  2. Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028-02]
  3. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  4. Departament de Salut, Generalitat de Catalunya, Spain
  5. GlaxoSmithKline
  6. United States National Institute of Mental Health [R01MH070884, MH077883]
  7. John D. and Catherine T. MacArthur Foundation
  8. Pfizer Foundation
  9. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  10. Fogarty International Center [FIRCA R03-TW006481]
  11. Pan American Health Organization
  12. Eli Lilly & Company Foundation
  13. Ortho-McNeil Pharmaceutical, Inc.
  14. Bristol-Myers Squibb
  15. Sanofi Aventis
  16. FOGARTY INTERNATIONAL CENTER [R03TW006481] Funding Source: NIH RePORTER
  17. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069864, R01MH070884, R13MH066849, R01MH077883] Funding Source: NIH RePORTER
  18. NATIONAL INSTITUTE ON DRUG ABUSE [K05DA015799, R01DA016558] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background: Information of the epidemiology of Major Depressive Episode (MDE) in Spain,one of the biggest southern European countries, is scarce and heterogeneous. The objective of this study was to assess the epidemiology of the disorder in the Spanish sample of the ESEMeD project. Methods: The ESEMED-Spain project is a cross-sectional, general population, household survey conducted with a representative sample of Spanish non-institutionalized adult population. The survey instrument was the CIDI 3.0, a structured diagnostic interview to assess disorders and treatment. Results: Lifetime prevalence was 10.6% while 12-month prevalence was 4.0%. A monotonic increase in lifetime overall prevalence was found from the youngest to the 50-64 cohort, declining then in the oldest group. Median age of onset was 30.0. Being a woman (OR = 2.7), previously married (OR = 1.8), unemployed or disabled to work (OR = 2.9) was associated to higher risk of 12-month-MDE. The highest comorbid associations were with dysthymia (OR = 73.1) and panic disorder (OR = 41.8). Limitations: 1. Psychiatric diagnoses were made by trained lay interviewers and this could have an imperfect sensitivity/specificity: 2. Individuals with mental illness could have more frequently rejected to participate in the survey; 3. Age-related recall bias could have affected the accuracy of age of onset estimates. Conclusions: The study shows that prevalence MDE in Spain is lower than in other Western countries. Important findings are the early age of onset, the high proportion of chronicity, and the high female/male ratio. Taken together, results offer a complex picture of the epidemiology of MDE in Spain, when compared to other countries in Europe. The role of cultural factors is discussed. (C) 2009 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据